A traditional Chinese medicine composition for treating allergic rhinitis and a preparation method thereof

Abstract

The application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating allergic rhinitis and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw medicinal materials through microbial fermentation with ultrasonic assistance: Schizonepeta, Ledebouriella, Radix Stellariae, Fructus Mume, Schisandra, Glycyrrhiza, Atractylodes, Astragalus, Punica granatum, Mentha, and Platycodon. The application further provides a preparation method of the traditional Chinese medicine composition: the raw medicinal materials are divided into volatile oil saponin group and polysaccharide organic acid group according to the chemical component characteristics, the induction liquid is prepared and inoculated with Saccharomyces cerevisiae and Lactobacillus plantarum for expansion culture, the remaining medicinal material powder is added into the induction expansion culture liquid, and aerobic fermentation and anaerobic fermentation are carried out under ultrasonic assistance, and the obtained fermentation liquids are combined and post-treated to obtain the traditional Chinese medicine composition. Through the synergistic process of grouping fermentation, ultrasonic assistance and induction expansion culture, the application realizes the significant improvement of the nasal symptoms of rats, and provides a new drug selection for the treatment of allergic rhinitis.

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition for treating allergic rhinitis and its preparation method. Background Technology

[0002] Allergic rhinitis (AR), also known as allergic rhinitis, is a type I hypersensitivity disease of the nasal mucosa mediated by immunoglobulin E (IgE). It is mainly triggered by allergen exposure, and typical clinical manifestations include paroxysmal sneezing, clear nasal discharge, nasal itching, and nasal congestion, severely impacting patients' work and quality of life. Currently, clinical treatment for AR primarily uses Western medicines such as antihistamines and nasal corticosteroids. While these can control symptoms to some extent, they are difficult to cure completely, and long-term use leads to numerous adverse reactions and a high relapse rate after discontinuation. Traditional Chinese medicine (TCM) offers treatment for AR with its multi-target, multi-pathway approach, significant efficacy, and fewer adverse reactions, and has gained widespread acceptance among patients.

[0003] However, existing traditional Chinese medicine compound preparation processes still have many shortcomings. Traditional Chinese medicine decoctions are mainly prepared by water decoction extraction. This method has the following limitations: First, prolonged decoction of diaphoretic herbs, aromatic herbs, and herbs with high volatile oil content can actually reduce or even eliminate the effective components. Second, once the concentration of effective components in the decoction reaches equilibrium between the medicinal materials and the liquid, continued decoction not only fails to extract more effective components but also reduces their concentration due to evaporation, or even destroys them under prolonged high temperatures, leading to decreased efficacy. Third, continued decoction after the effective components have reached equilibrium may cause non-effective components to dissolve continuously, affecting the quality of the liquid. Fourth, for herbs containing high levels of polysaccharides and starch, the surface starch easily gelatinizes, making it difficult to extract the effective components. Fifth, the traditional decoction process is complex, labor-intensive, and prone to significant variations depending on the individual herbs. Furthermore, traditional decoction is a purely physical extraction process that lacks the biotransformation step of large molecular active ingredients in medicinal materials. This makes it difficult to fully degrade these components into more easily absorbed small molecular active substances, thus limiting the full realization of the medicinal efficacy. Therefore, there is an urgent need to develop an AR (anti-inflammatory) method for preparing traditional Chinese medicine that can overcome the shortcomings of traditional decoction processes and improve the utilization rate of active ingredients. Summary of the Invention

[0004] The purpose of this invention is to provide a traditional Chinese medicine composition for treating allergic rhinitis and its preparation method, so as to solve the above-mentioned technical problems.

[0005] To achieve the above-mentioned technical objectives, the technical solution of the present invention is as follows: A traditional Chinese medicine composition for treating allergic rhinitis is made from the following raw medicinal materials by ultrasonic-assisted bidirectional microbial fermentation in parts by weight: 8-12 parts of Schizonepeta tenuifolia, 8-12 parts of Saposhnikovia divaricata, 8-12 parts of Stellaria dichotoma, 8-12 parts of Prunus mume, 8-12 parts of Schisandra chinensis, 8-12 parts of Glycyrrhiza uralensis, 8-12 parts of Atractylodes macrocephala, 12-18 parts of Astragalus membranaceus, 8-12 parts of Punica granatum peel, 4-8 parts of Mentha haplocalyx, and 8-12 parts of Platycodon grandiflorus.

[0006] This invention also provides a method for preparing a traditional Chinese medicine composition for treating allergic rhinitis, comprising the following steps: S1. Weigh each raw medicinal material according to the weight parts, and divide each raw medicinal material into volatile oil saponin group and polysaccharide organic acid group. Perform low-temperature ultrafine pulverization on the volatile oil saponin group and sieve to obtain volatile oil saponin group powder; perform room temperature pulverization on the polysaccharide organic acid group and sieve to obtain polysaccharide organic acid group powder. S2. Take 20-40% of the mass of the volatile oil saponin group powder and the polysaccharide organic acid group powder respectively to prepare the volatile oil saponin group induction solution and the polysaccharide organic acid group induction solution; inoculate Saccharomyces cerevisiae into the volatile oil saponin group induction solution for aerobic expansion culture to obtain Saccharomyces cerevisiae induction expansion solution; inoculate Lactobacillus plantarum into the polysaccharide organic acid group induction solution for anaerobic expansion culture to obtain Lactobacillus plantarum induction expansion solution; S3. Take the remaining volatile oil saponin powder, add 6-10 times the mass of distilled water, add Saccharomyces cerevisiae induction culture medium, and carry out aerobic ultrasonic fermentation culture to obtain aerobic fermentation broth; take the remaining polysaccharide organic acid powder, add 6-10 times the mass of distilled water, add Lactobacillus plantarum induction culture medium, and carry out anaerobic ultrasonic fermentation culture to obtain anaerobic fermentation broth. S4. Combine the aerobic fermentation broth and the anaerobic fermentation broth to obtain a combined fermentation broth, which is then sterilized, inactivated, separated from solids, and concentrated to obtain a traditional Chinese medicine composition for treating allergic rhinitis.

[0007] As a further improvement, in step S1, the volatile oil saponin group is composed of Schizonepeta tenuifolia, Saposhnikovia divaricata, Mentha haplocalyx, Stellaria dichotoma and Platycodon grandiflorus; the polysaccharide organic acid group is composed of Astragalus membranaceus, Atractylodes macrocephala, Glycyrrhiza uralensis, Prunus mume, Schisandra chinensis and Punica granatum peel.

[0008] As a further improvement, in step S2, the preparation method of the volatile oil saponin group induction solution is as follows: take 20-40% of the mass of the volatile oil saponin group powder, add 6-10 times the mass of the powder in distilled water, soak for 20-40 minutes, decoct for 15-20 minutes, filter, and obtain the first decoction; add 4-8 times the mass of the powder in distilled water to the residue, decoct for 10-15 minutes, filter, and obtain the second decoction; combine the two decoctions, concentrate under reduced pressure, add 1-3% w / v glucose, sterilize, and obtain the volatile oil saponin group induction solution; The preparation method of the polysaccharide-organic acid group induction solution is as follows: Take 20-40% of the mass of the polysaccharide-organic acid group powder, add 6-10 times the mass of the powder in distilled water, soak for 40-60 minutes, decoct for 25-35 minutes, filter, and obtain the first decoction; add 4-8 times the mass of the powder in distilled water to the residue, decoct for 15-25 minutes, filter, and obtain the second decoction; combine the two decoctions, concentrate under reduced pressure, add 1-3% w / v glucose, sterilize, and obtain the polysaccharide-organic acid group induction solution.

[0009] As a further improvement, in step S2, the conditions for aerobic expansion culture are: temperature 28~32℃, rotation speed 120~180r / min, and culture time 18~30h; the conditions for anaerobic expansion culture are: temperature 35~39℃, anaerobic environment, and static culture for 18~30h.

[0010] As a further improvement, in step S3, the conditions for aerobic ultrasonic fermentation culture are: ultrasonic frequency 28kHz, power density 0.04~0.15W / mL, intermittent ultrasonic mode, fermentation temperature 28~32℃, rotation speed 120~180r / min, and fermentation time 24~48h; the conditions for anaerobic ultrasonic fermentation culture are: ultrasonic frequency 40kHz, power density 0.05~0.12W / mL, intermittent ultrasonic mode, fermentation temperature 35~39℃, anaerobic environment, and static fermentation for 48~60h.

[0011] As a further improvement, in step S4, the sterilization and inactivation method is pasteurization; the solid-liquid separation method is centrifugation and membrane filtration; and the concentration is vacuum concentration to 20-30% of the combined fermentation broth volume.

[0012] Due to the adoption of the above technical solution, the beneficial effects of the present invention are as follows: This formula uses Astragalus membranaceus as the principal herb, which invigorates Qi, strengthens the defensive Qi, and consolidates the pores, thus replenishing lung Qi and securing the nasal passages, fundamentally reducing the invasion of external pathogens. Atractylodes macrocephala, Saposhnikovia divaricata, Schizonepeta tenuifolia, and Mentha haplocalyx serve as assistant herbs. Atractylodes macrocephala invigorates the spleen and invigorates Qi, nourishing the earth element to generate metal, assisting Astragalus membranaceus in tonifying the lungs and consolidating the exterior. Saposhnikovia divaricata dispels wind, releases the exterior, eliminates dampness, and relieves itching; when combined with Astragalus membranaceus, it consolidates the exterior without retaining pathogens and disperses pathogens without harming the body's vital energy. Schizonepeta tenuifolia dispels wind and pathogens, specifically targeting the skin surface and nasal passages, assisting Saposhnikovia divaricata in dispelling wind and relieving itching. Mentha haplocalyx, being light and ascending, clears the nasal passages, relieves nasal itching, and can also counteract the effects of Astragalus membranaceus. Atractylodes macrocephala and other warming tonics can cause excessive heat; Prunus mume and Schisandra chinensis are added to nourish yin and generate fluids, replenish qi and astringe the lungs; Pomegranate peel is used to astringe and consolidate, and these three help Astragalus membranaceus, the chief herb, to astringe lung qi and reduce excessive leakage of body fluids; Stellaria dichotoma is sweet and cold to nourish yin, clear heat and cool blood; Glycyrrhiza uralensis is used as the guide to harmonize the various herbs, alleviate the pungent and astringent properties, and also replenish qi and harmonize the middle jiao; This formula is based on replenishing qi and consolidating the exterior, combined with astringent properties to astringe the lungs, and supplemented with dispelling wind and opening the nasal passages; It is suitable for allergic rhinitis caused by deficiency of lung and spleen qi, wind-evil binding the nose, and hyperresponsiveness of the nasal mucosa.

[0013] This invention creatively employs a synergistic approach of group fermentation, ultrasound-assisted fermentation, and induced amplification in its preparation process, overcoming the limitations of traditional Chinese medicine decoction or single fermentation. Based on the chemical composition characteristics of the medicinal materials, they are divided into a volatile oil saponin group and a polysaccharide and organic acid group. The volatile oil saponin group is inoculated with *Saccharomyces cerevisiae* for aerobic fermentation, primarily targeting the transformation of volatile oils and saponins; the polysaccharide and organic acid group is inoculated with *Lactobacillus plantarum* for anaerobic fermentation, primarily targeting the degradation and transformation of polysaccharides, organic acids, and tannins. Both groups of medicinal materials undergo targeted biotransformation by specific bacterial strains under their respective optimal conditions, avoiding mutual inhibition between aerobic and anaerobic bacteria in the same system and preventing oxidative loss of volatile oil components during prolonged fermentation.

[0014] This invention employs a two-stage strategy: pre-induction during the expansion phase and deep transformation during the fermentation phase. During the expansion phase, an induction solution is prepared from a portion of the medicinal materials to induce the microbial strain, ensuring continuous contact between the strain and the active ingredients of the traditional Chinese medicine during the expansion process, thereby enhancing the strain's adaptability to the medicine. During the fermentation phase, the expanded microbial strain is mixed with the remaining medicinal materials, and ultrasonic assistance is applied in real time during fermentation. Through cavitation and microfluidic effects, the exchange of substances between the microbial cells and the medicinal substrate is promoted, accelerating the biotransformation of the active ingredients and achieving a deep integration of microbial expansion and traditional Chinese medicine fermentation.

[0015] The grouped ultrasound-microbial bidirectional fermentation process established in this invention can be used not only for traditional Chinese medicine compositions for treating allergic rhinitis, but also for other traditional Chinese medicine compositions, which is conducive to promoting the development of innovative traditional Chinese medicine drugs, improved new traditional Chinese medicine drugs, and traditional Chinese medicine compound preparations based on ancient classic prescriptions. Attached Figure Description

[0016] Figure 1 These are the growth curves of Saccharomyces cerevisiae and Lactobacillus plantarum. Figure a shows the growth curve of Saccharomyces cerevisiae, and Figure b shows the growth curve of Lactobacillus plantarum. Figure 2 These are the detection results of ALT and AST in rats. Figure a shows the ALT results, and Figure b shows the AST results. Figure 3 These are the detection results of CREA and UREA in rats. Figure a shows the results of CREA, and Figure b shows the results of UREA. Figure 4 These are the results of wet weight measurements of rat liver and kidney. Figure a shows the results of liver wet weight, and Figure b shows the results of kidney wet weight. Detailed Implementation

[0017] The technical solution of the present invention will be clearly and completely described below with reference to specific embodiments. However, those skilled in the art will understand that the embodiments described below are some embodiments of the present invention, but not all embodiments, and are only used to illustrate the present invention, and should not be regarded as limiting the scope of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention. Where specific conditions are not specified in the embodiments, conventional conditions or manufacturer's conditions shall be followed. Where the manufacturers of reagents or instruments are not specified, they are all conventional products that can be purchased commercially.

[0018] The strains used in the embodiments, comparative examples, and experiments in this patent are all commercially available strains: Saccharomyces cerevisiae (Saccharomyces cerevisiae). Saccharomyces cerevisiae CGMCC 2.1881, Lactobacillus plantarum ( Lactobacillus plantarum CGMCC 1.557.

[0019] The Chinese medicinal materials used in this patent are: Schizonepeta tenuifolia (origin: Jiangsu), Saposhnikovia divaricata (origin: Jilin), Stellaria dichotoma (origin: Ningxia), Prunus mume (origin: Sichuan), Schisandra chinensis (origin: Liaoning), Glycyrrhiza uralensis (origin: Inner Mongolia), Atractylodes macrocephala (origin: Anhui), Astragalus membranaceus (origin: Inner Mongolia), Mentha haplocalyx (origin: Jiangsu), and Platycodon grandiflorus (origin: Anhui), which were purchased from Beijing Tongrentang Suzhou Street Pharmaceutical Co., Ltd., and pomegranate peel was purchased from Kangmei Pharmaceutical Co., Ltd.

[0020] Example 1: A method for preparing a traditional Chinese medicine composition for treating allergic rhinitis, comprising the following steps: 1. Weigh the raw medicinal materials according to the prescription: 10g of Schizonepeta tenuifolia, 10g of Saposhnikovia divaricata, 10g of Stellaria dichotoma, 10g of Prunus mume, 10g of Schisandra chinensis, 10g of Glycyrrhiza uralensis, 10g of Atractylodes macrocephala, 15g of Astragalus membranaceus, 10g of Punica granatum peel, 6g of Mentha haplocalyx, and 10g of Platycodon grandiflorus. Divide the raw medicinal materials into two groups based on their chemical composition: the volatile oil saponin group consists of Schizonepeta tenuifolia, Saposhnikovia divaricata, Mentha haplocalyx, Stellaria dichotoma, and Platycodon grandiflorus, with a total weight of 46g; the polysaccharide and organic acid group consists of Astragalus membranaceus, Atractylodes macrocephala, Glycyrrhiza uralensis, Prunus mume, Schisandra chinensis, and Punica granatum peel, with a total weight of 65g. Place the volatile oil saponin group in an ultrafine pulverizer, cool it with liquid nitrogen during the pulverization process, maintain the material temperature ≤0℃, and perform low-temperature ultrafine pulverization. Pass the powder through a 100-mesh sieve to obtain the volatile oil saponin powder, and seal it for later use. Place the polysaccharide and organic acid group in a room-temperature pulverizer, pulverize it, pass it through a 60-mesh sieve to obtain the polysaccharide and organic acid powder, and seal it for later use.

[0021] 2. Take 13.8g of volatile oil saponin powder, add 110mL of distilled water, soak at room temperature for 30min, heat to boiling, then simmer for 17min, filter, collect the first decoction filtrate, add 83mL of distilled water to the residue, decoct for 12min, filter, collect the second decoction filtrate, combine the two filtrates, concentrate under reduced pressure at 50℃ and -0.08MPa to a crude drug concentration of 0.5g / mL, add 2% w / v glucose, stir to dissolve, autoclave at 121℃ for 20min to obtain volatile oil saponin induction solution, cool to room temperature for later use.

[0022] Take 19.5g of polysaccharide-organic acid powder, add 156mL of distilled water, soak at room temperature for 50min, heat to boiling, then simmer for 30min, filter, collect the first decoction filtrate, add 117mL of distilled water to the residue, simmer for 20min, filter, collect the second decoction filtrate, combine the two filtrates, concentrate under reduced pressure at 55℃ and -0.08MPa to a crude drug concentration of 0.5g / mL, add 2% w / v glucose, stir to dissolve, autoclave at 121℃ for 20min to obtain the polysaccharide-organic acid induction solution, cool to room temperature for later use.

[0023] 3. Thaw cryopreservation tubes of *Saccharomyces cerevisiae* rapidly in a 37°C water bath, inoculate them onto YPD solid medium plates (10 g / L yeast extract, 20 g / L peptone, 20 g / L glucose, 20 g / L agar), and incubate at 30°C for 48 h. Thaw cryopreservation tubes of *Lactobacillus plantarum* rapidly in a 37°C water bath, inoculate them onto MRS solid medium (10 g / L peptone, 10 g / L beef extract, 5 g / L yeast extract, 20 g / L glucose, 5 g / L sodium acetate, 2 g / L diammonium citrate, 1 mL / L Tween 80, 2 g / L K₂HPO₄, 0.58 g / L MgSO₄·7H₂O, 0.25 g / L MnSO₄·H₂O, 20 g / L agar, pH 10). 6.5) Plates, anaerobic culture at 37℃ for 48h; pick single colonies from each plate and inoculate them into the corresponding liquid culture medium, and culture them at the same temperature until the logarithmic growth phase to obtain the activated seed solution.

[0024] 4. Inoculate the activated seed culture of Saccharomyces cerevisiae at a rate of 5% v / v into the volatile oil saponin group induction solution and culture at 30℃ and 150 r / min for 24 h to obtain the Saccharomyces cerevisiae induction expansion solution; inoculate the activated seed culture of Lactobacillus plantarum at a rate of 4% v / v into the polysaccharide organic acid group induction solution and culture in an anaerobic environment at 37℃ for 24 h to obtain the Lactobacillus plantarum induction expansion solution.

[0025] 5. Take 32.2g of the remaining volatile oil saponin powder, add 258mL of distilled water, place it in an ultrasonic-fermentation coupled reactor, add the Saccharomyces cerevisiae induction culture medium, stir evenly, and set the ultrasonic parameters as follows: frequency 28kHz, power density 0.1W / mL, using intermittent ultrasonic mode (ultrasound for 5min, pause for 15min, repeat); fermentation conditions are: temperature 30℃, rotation speed 150r / min, aeration rate 1.0vvm (sterile air introduced), and fermentation time 36h. After fermentation, an aerobic fermentation broth is obtained.

[0026] Take 45.5g of the remaining polysaccharide-organic acid powder, add 364mL of distilled water, place it in an ultrasonic-fermentation coupled reactor, and purge the air in the reactor with high-purity N2 for 10min to create an anaerobic environment. Add the Lactobacillus plantarum induction culture medium, stir evenly, and set the ultrasonic parameters as follows: frequency 40kHz, power density 0.08W / mL, and use intermittent ultrasonic mode (ultrasound for 5min, pause for 15min, repeat). The fermentation conditions are: temperature 37℃, continuous N2 purging to maintain the anaerobic environment, static fermentation for 56h, and after fermentation, obtain the anaerobic fermentation broth.

[0027] 6. Combine the aerobic fermentation broth and the anaerobic fermentation broth, stir evenly to obtain a combined fermentation broth; heat the combined fermentation broth to 80℃, maintain for 30 min, and quickly cool to room temperature; centrifuge at 8000 r / min for 15 min, collect the supernatant, and filter the supernatant through a 0.45 μm microporous membrane to obtain a clear filtrate; place the clear filtrate in a rotary evaporator and concentrate under reduced pressure at 50℃ and -0.08 MPa to 25% of the combined fermentation broth volume to obtain a traditional Chinese medicine composition for treating allergic rhinitis.

[0028] Example 2: A method for preparing a traditional Chinese medicine composition for treating allergic rhinitis, comprising the following steps: 1. Weigh the raw medicinal materials according to the prescription: 8g of Schizonepeta tenuifolia, 8g of Saposhnikovia divaricata, 8g of Stellaria dichotoma, 12g of Prunus mume, 12g of Schisandra chinensis, 12g of Glycyrrhiza uralensis, 12g of Atractylodes macrocephala, 18g of Astragalus membranaceus, 12g of Punica granatum peel, 4g of Mentha haplocalyx, and 8g of Platycodon grandiflorus. Divide the raw medicinal materials into two groups based on their chemical composition: the volatile oil saponin group consists of Schizonepeta tenuifolia, Saposhnikovia divaricata, Mentha haplocalyx, Stellaria dichotoma, and Platycodon grandiflorus, with a total weight of 36g; the polysaccharide and organic acid group consists of Astragalus membranaceus, Atractylodes macrocephala, Glycyrrhiza uralensis, Prunus mume, Schisandra chinensis, and Punica granatum peel, with a total weight of 78g. Place the volatile oil saponin group in an ultrafine pulverizer, cool it with liquid nitrogen during the pulverization process, maintain the material temperature ≤0℃, and perform low-temperature ultrafine pulverization. Pass the powder through a 100-mesh sieve to obtain the volatile oil saponin powder, and seal it for later use. Place the polysaccharide and organic acid group in a room-temperature pulverizer, pulverize it, pass it through a 60-mesh sieve to obtain the polysaccharide and organic acid powder, and seal it for later use.

[0029] 2. Take 7.2g of volatile oil saponin powder, add 43.2mL of distilled water, soak at room temperature for 20min, heat to boiling, then simmer for 15min, filter, collect the first decoction filtrate, add 28.8mL of distilled water to the residue, decoct for 10min, filter, collect the second decoction filtrate, combine the two filtrates, concentrate under reduced pressure at 50℃ and -0.08MPa to a crude drug concentration of 0.5g / mL, add 1% w / v glucose, stir to dissolve, autoclave at 121℃ for 20min to obtain volatile oil saponin induction solution, cool to room temperature for later use.

[0030] Take 15.6g of polysaccharide-organic acid powder, add 93.6mL of distilled water, soak at room temperature for 40min, heat to boiling, then simmer for 25min, filter, collect the first decoction filtrate, add 62.4mL of distilled water to the residue, decoct for 15min, filter, collect the second decoction filtrate, combine the two filtrates, concentrate under reduced pressure at 55℃ and -0.08MPa to a crude drug concentration of 0.5g / mL, add 1% w / v glucose, stir to dissolve, autoclave at 121℃ for 20min to obtain the polysaccharide-organic acid induction solution, cool to room temperature for later use.

[0031] 3. Thaw cryopreservation tubes of *Saccharomyces cerevisiae* rapidly in a 37°C water bath, inoculate them onto YPD solid medium plates (10 g / L yeast extract, 20 g / L peptone, 20 g / L glucose, 20 g / L agar), and incubate at 30°C for 48 h. Thaw cryopreservation tubes of *Lactobacillus plantarum* rapidly in a 37°C water bath, inoculate them onto MRS solid medium (10 g / L peptone, 10 g / L beef extract, 5 g / L yeast extract, 20 g / L glucose, 5 g / L sodium acetate, 2 g / L diammonium citrate, 1 mL / L Tween 80, 2 g / L K₂HPO₄, 0.58 g / L MgSO₄·7H₂O, 0.25 g / L MnSO₄·H₂O, 20 g / L agar, pH 10). 6.5) Plates, anaerobic culture at 37℃ for 48h; pick single colonies from each plate and inoculate them into the corresponding liquid culture medium, and culture them at the same temperature until the logarithmic growth phase to obtain the activated seed solution.

[0032] 4. Inoculate the activated seed culture of Saccharomyces cerevisiae at a rate of 5% v / v into the volatile oil saponin group induction solution and culture at 28℃ and 120r / min for 18h to obtain the Saccharomyces cerevisiae induction expansion solution; inoculate the activated seed culture of Lactobacillus plantarum at a rate of 4% v / v into the polysaccharide organic acid group induction solution and culture in an anaerobic environment at 35℃ for 18h to obtain the Lactobacillus plantarum induction expansion solution.

[0033] 5. Take 28.8g of the remaining volatile oil saponin powder, add 172.8mL of distilled water, place it in an ultrasonic-fermentation coupled reactor, add the brewing yeast induction culture medium, stir evenly, and set the ultrasonic parameters as follows: frequency 28kHz, power density 0.04W / mL, using intermittent ultrasonic mode (ultrasound for 5min, pause for 15min, repeat); fermentation conditions are: temperature 28℃, rotation speed 120r / min, aeration rate 1.0vvm (sterile air introduced), fermentation time 24h, after fermentation, aerobic fermentation broth is obtained.

[0034] Take 62.4g of the remaining polysaccharide-organic acid powder, add 374.4mL of distilled water, place it in an ultrasonic-fermentation coupled reactor, and purge the air in the reactor with high-purity N2 for 10min to create an anaerobic environment. Add the Lactobacillus plantarum induction culture medium, stir evenly, and set the ultrasonic parameters as follows: frequency 40kHz, power density 0.05W / mL, and use intermittent ultrasonic mode (ultrasound for 5min, pause for 15min, repeat). The fermentation conditions are: temperature 35℃, continuous N2 purging to maintain the anaerobic environment, static fermentation for 48h, and after fermentation, obtain the anaerobic fermentation broth.

[0035] 6. Combine the aerobic fermentation broth and the anaerobic fermentation broth, stir evenly to obtain a combined fermentation broth; heat the combined fermentation broth to 75℃, maintain for 40 min, and rapidly cool to room temperature; centrifuge at 8000 r / min for 15 min, collect the supernatant, and filter the supernatant through a 0.45 μm microporous membrane to obtain a clear filtrate; place the clear filtrate in a rotary evaporator and concentrate under reduced pressure at 50℃ and -0.08 MPa to 30% of the combined fermentation broth volume to obtain a traditional Chinese medicine composition for treating allergic rhinitis.

[0036] Example 3: A method for preparing a traditional Chinese medicine composition for treating allergic rhinitis, comprising the following steps: 1. Weigh the raw medicinal materials according to the prescription: 12g of Schizonepeta tenuifolia, 12g of Saposhnikovia divaricata, 12g of Stellaria dichotoma, 8g of Prunus mume, 8g of Schisandra chinensis, 8g of Glycyrrhiza uralensis, 8g of Atractylodes macrocephala, 12g of Astragalus membranaceus, 8g of Punica granatum peel, 8g of Mentha haplocalyx, and 12g of Platycodon grandiflorus. Divide the raw medicinal materials into two groups based on their chemical composition: the volatile oil saponin group consists of Schizonepeta tenuifolia, Saposhnikovia divaricata, Mentha haplocalyx, Stellaria dichotoma, and Platycodon grandiflorus, with a total weight of 56g; the polysaccharide and organic acid group consists of Astragalus membranaceus, Atractylodes macrocephala, Glycyrrhiza uralensis, Prunus mume, Schisandra chinensis, and Punica granatum peel, with a total weight of 52g. Place the volatile oil saponin group in an ultrafine pulverizer, cool it with liquid nitrogen during the pulverization process, maintain the material temperature ≤0℃, and perform low-temperature ultrafine pulverization. Pass the powder through a 100-mesh sieve to obtain the volatile oil saponin powder, and seal it for later use. Place the polysaccharide and organic acid group in a room-temperature pulverizer, pulverize it, pass it through a 60-mesh sieve to obtain the polysaccharide and organic acid powder, and seal it for later use.

[0037] 2. Take 22.4g of volatile oil saponin powder, add 224mL of distilled water, soak at room temperature for 40min, heat to boiling, then simmer for 20min, filter, collect the first decoction filtrate, add 179.2mL of distilled water to the residue, decoct for 15min, filter, collect the second decoction filtrate, combine the two filtrates, concentrate under reduced pressure at 50℃ and -0.08MPa to a crude drug concentration of 0.4g / mL, add 3% w / v glucose, stir to dissolve, autoclave at 121℃ for 20min to obtain volatile oil saponin induction solution, cool to room temperature for later use.

[0038] Take 20.8g of polysaccharide-organic acid powder, add 208mL of distilled water, soak at room temperature for 60min, heat to boiling, then simmer for 35min, filter, collect the first decoction filtrate, add 166.4mL of distilled water to the residue, decoct for 25min, filter, collect the second decoction filtrate, combine the two filtrates, concentrate under reduced pressure at 55℃ and -0.08MPa to a crude drug concentration of 0.4g / mL, add 3% w / v glucose, stir to dissolve, autoclave at 121℃ for 20min to obtain the polysaccharide-organic acid induction solution, cool to room temperature for later use.

[0039] 3. Thaw cryopreservation tubes of *Saccharomyces cerevisiae* rapidly in a 37°C water bath, inoculate them onto YPD solid medium plates (10 g / L yeast extract, 20 g / L peptone, 20 g / L glucose, 20 g / L agar), and incubate at 30°C for 48 h. Thaw cryopreservation tubes of *Lactobacillus plantarum* rapidly in a 37°C water bath, inoculate them onto MRS solid medium (10 g / L peptone, 10 g / L beef extract, 5 g / L yeast extract, 20 g / L glucose, 5 g / L sodium acetate, 2 g / L diammonium citrate, 1 mL / L Tween 80, 2 g / L K₂HPO₄, 0.58 g / L MgSO₄·7H₂O, 0.25 g / L MnSO₄·H₂O, 20 g / L agar, pH 10). 6.5) Plates, anaerobic culture at 37℃ for 48h; pick single colonies from each plate and inoculate them into the corresponding liquid culture medium, and culture them at the same temperature until the logarithmic growth phase to obtain the activated seed solution.

[0040] 4. Inoculate the activated seed culture of Saccharomyces cerevisiae at a rate of 5% v / v into the volatile oil saponin group induction solution and culture at 32℃ and 180r / min for 30h to obtain the Saccharomyces cerevisiae induction expansion solution; inoculate the activated seed culture of Lactobacillus plantarum at a rate of 4% v / v into the polysaccharide organic acid group induction solution and culture in an anaerobic environment at 39℃ for 30h to obtain the Lactobacillus plantarum induction expansion solution.

[0041] 5. Take 33.6g of the remaining volatile oil saponin powder, add 336mL of distilled water, place it in an ultrasonic-fermentation coupled reactor, add the Saccharomyces cerevisiae induction culture medium, stir evenly, and set the ultrasonic parameters as follows: frequency 28kHz, power density 0.15W / mL, using intermittent ultrasonic mode (ultrasound for 5min, pause for 15min, repeat); fermentation conditions are: temperature 32℃, rotation speed 180r / min, aeration rate 1.0vvm (sterile air introduced), and fermentation time 48h. After fermentation, an aerobic fermentation broth is obtained.

[0042] Take 31.2g of the remaining polysaccharide-organic acid powder, add 312mL of distilled water, place it in an ultrasonic-fermentation coupled reactor, and purge the air in the reactor with high-purity N2 for 10min to create an anaerobic environment. Add the Lactobacillus plantarum induction culture medium, stir evenly, and set the ultrasonic parameters as follows: frequency 40kHz, power density 0.12W / mL, and use intermittent ultrasonic mode (ultrasound for 5min, pause for 15min, repeat). The fermentation conditions are: temperature 39℃, continuous N2 purging to maintain the anaerobic environment, static fermentation for 60h, and after fermentation, obtain the anaerobic fermentation broth.

[0043] 6. Combine the aerobic fermentation broth and the anaerobic fermentation broth, stir evenly to obtain a combined fermentation broth; heat the combined fermentation broth to 85℃, maintain for 20 min, and rapidly cool to room temperature; centrifuge at 8000 r / min for 15 min, collect the supernatant, and filter the supernatant through a 0.45 μm microporous membrane to obtain a clear filtrate; place the clear filtrate in a rotary evaporator and concentrate under reduced pressure at 50℃ and -0.08 MPa to 20% of the combined fermentation broth volume to obtain a traditional Chinese medicine composition for treating allergic rhinitis.

[0044] Comparative Example 1: A method for preparing a traditional Chinese medicine composition for treating allergic rhinitis, differing from Example 1 in that the traditional Chinese medicine is processed using a conventional water decoction method, including the following steps: Weigh the raw medicinal materials according to the prescription in Example 1: 10g of Schizonepeta tenuifolia, 10g of Saposhnikovia divaricata, 10g of Stellaria dichotoma, 10g of Prunus mume, 10g of Schisandra chinensis, 10g of Glycyrrhiza uralensis, 10g of Atractylodes macrocephala, 15g of Astragalus membranaceus, 10g of Punica granatum peel, 6g of Mentha haplocalyx, and 10g of Platycodon grandiflorus. Mix all the medicinal materials, add 8 times the amount of distilled water, soak at room temperature for 30 minutes, heat to a boil, and then simmer for 30 minutes. Filter and collect the first decoction. Add 6 times the amount of distilled water to the dregs, heat to a boil, and then simmer for 20 minutes. Filter and collect the second decoction. Combine the two filtrates and concentrate under reduced pressure at 50℃ and -0.08MPa to the same volume as in step 6 of Example 1 to obtain a conventional decoction. Centrifuge at 8000r / min for 15 minutes, collect the supernatant, and then filter the supernatant through a 0.45μm microporous membrane to obtain a traditional Chinese medicine composition for treating allergic rhinitis.

[0045] Comparative Example 2: A method for preparing a traditional Chinese medicine composition for treating allergic rhinitis, differing from Example 1 in that the fermentation process is not ultrasound-assisted, and includes the following steps: 1. Weigh the raw medicinal materials according to the prescription: 10g of Schizonepeta tenuifolia, 10g of Saposhnikovia divaricata, 10g of Stellaria dichotoma, 10g of Prunus mume, 10g of Schisandra chinensis, 10g of Glycyrrhiza uralensis, 10g of Atractylodes macrocephala, 15g of Astragalus membranaceus, 10g of Punica granatum peel, 6g of Mentha haplocalyx, and 10g of Platycodon grandiflorus. Divide the raw medicinal materials into two groups based on their chemical composition: the volatile oil saponin group consists of Schizonepeta tenuifolia, Saposhnikovia divaricata, Mentha haplocalyx, Stellaria dichotoma, and Platycodon grandiflorus, with a total weight of 46g; the polysaccharide and organic acid group consists of Astragalus membranaceus, Atractylodes macrocephala, Glycyrrhiza uralensis, Prunus mume, Schisandra chinensis, and Punica granatum peel, with a total weight of 65g. Place the volatile oil saponin group in an ultrafine pulverizer, cool it with liquid nitrogen during the pulverization process, maintain the material temperature ≤0℃, and perform low-temperature ultrafine pulverization. Pass the powder through a 100-mesh sieve to obtain the volatile oil saponin powder, and seal it for later use. Place the polysaccharide and organic acid group in a room-temperature pulverizer, pulverize it, pass it through a 60-mesh sieve to obtain the polysaccharide and organic acid powder, and seal it for later use.

[0046] 2. Take 13.8g of volatile oil saponin powder, add 110mL of distilled water, soak at room temperature for 30min, heat to boiling, then simmer for 17min, filter, collect the first decoction filtrate, add 83mL of distilled water to the residue, decoct for 12min, filter, collect the second decoction filtrate, combine the two filtrates, concentrate under reduced pressure at 50℃ and -0.08MPa to a crude drug concentration of 0.5g / mL, add 2% w / v glucose, stir to dissolve, autoclave at 121℃ for 20min to obtain volatile oil saponin induction solution, cool to room temperature for later use. Take 19.5g of polysaccharide-organic acid powder, add 156mL of distilled water, soak at room temperature for 50min, heat to boiling, then simmer for 30min, filter, collect the first decoction filtrate, add 117mL of distilled water to the residue, simmer for 20min, filter, collect the second decoction filtrate, combine the two filtrates, concentrate under reduced pressure at 55℃ and -0.08MPa to a crude drug concentration of 0.5g / mL, add 2% w / v glucose, stir to dissolve, autoclave at 121℃ for 20min to obtain the polysaccharide-organic acid induction solution, cool to room temperature for later use.

[0047] 3. Thaw the cryopreserved Saccharomyces cerevisiae tubes rapidly in a 37°C water bath, inoculate them onto YPD solid medium plates, and incubate them at 30°C for 48 hours; thaw the cryopreserved Lactobacillus plantarum tubes rapidly in a 37°C water bath, inoculate them onto MRS solid medium plates, and incubate them anaerobically at 37°C for 48 hours; pick single colonies from each plate and inoculate them into the corresponding liquid medium, and incubate them at the same temperature until the logarithmic growth phase to obtain the activated seed culture.

[0048] 4. Inoculate the activated seed culture of Saccharomyces cerevisiae at a rate of 5% v / v into the volatile oil saponin group induction solution and culture at 30℃ and 150 r / min for 24 h to obtain the Saccharomyces cerevisiae induction expansion solution; inoculate the activated seed culture of Lactobacillus plantarum at a rate of 4% v / v into the polysaccharide organic acid group induction solution and culture in an anaerobic environment at 37℃ for 24 h to obtain the Lactobacillus plantarum induction expansion solution.

[0049] 5. Take 32.2g of the remaining volatile oil saponin powder, add 258mL of distilled water, place it in a fermentation reactor, add the Saccharomyces cerevisiae induction culture medium, stir evenly, without ultrasonic assistance, fermentation conditions are 30℃, rotation speed 150r / min, aeration rate 1.0vvm (sterile air), fermentation time 36h. After fermentation, the aerobic fermentation broth is obtained. Take 45.5g of the remaining polysaccharide organic acid powder, add 364mL of distilled water, place it in a fermentation reactor, purge the air in the reactor with high-purity N2 for 10min to create an anaerobic environment, add the Lactobacillus plantarum induction culture medium, stir evenly, without ultrasonic assistance, fermentation conditions are 37℃, continuously purge with N2 to maintain the anaerobic environment, let it ferment statically for 56h, after fermentation, the anaerobic fermentation broth is obtained.

[0050] 6. Combine the aerobic fermentation broth and the anaerobic fermentation broth, stir evenly to obtain a combined fermentation broth; heat the combined fermentation broth to 80℃, maintain for 30 min, and quickly cool to room temperature; centrifuge at 8000 r / min for 15 min, collect the supernatant, and filter the supernatant through a 0.45 μm microporous membrane to obtain a clear filtrate; place the clear filtrate in a rotary evaporator and concentrate under reduced pressure at 50℃ and -0.08 MPa to 25% of the combined fermentation broth volume to obtain a traditional Chinese medicine composition for treating allergic rhinitis.

[0051] Comparative Example 3: A method for preparing a traditional Chinese medicine composition for treating allergic rhinitis, differing from Example 1 in that the fermentation process involves mixed fermentation of two strains without group fermentation, and includes the following steps: 1. Weigh the raw medicinal materials according to the prescription: 10g of Schizonepeta tenuifolia, 10g of Saposhnikovia divaricata, 10g of Stellaria dichotoma, 10g of Prunus mume, 10g of Schisandra chinensis, 10g of Glycyrrhiza uralensis, 10g of Atractylodes macrocephala, 15g of Astragalus membranaceus, 10g of Punica granatum peel, 6g of Mentha haplocalyx, and 10g of Platycodon grandiflorus. Mix all 11 medicinal materials together, place them in an ultra-micro pulverizer, pulverize at room temperature, and pass them through a 60-mesh sieve to obtain mixed medicinal powder with a total weight of 111g. Seal and store for later use.

[0052] 2. Take 33.3g of mixed medicinal powder, add 266mL of distilled water, soak at room temperature for 30min, heat to boiling, then simmer for 30min, filter, and collect the first decoction filtrate; add 200mL of distilled water to the dregs, decoct for 20min, filter, and collect the second decoction filtrate; combine the two filtrates, concentrate under reduced pressure at 50℃ and -0.08MPa to a crude drug concentration of 0.5g / mL, add 2% w / v glucose, stir to dissolve, autoclave at 121℃ for 20min to obtain a mixed induction solution, cool to room temperature for later use.

[0053] 3. The brewer's yeast and Lactobacillus plantarum were activated and cultured to the logarithmic growth phase according to the method in Example 1, and used as activation seed solutions.

[0054] 4. Simultaneously inoculate the activated seed culture of Saccharomyces cerevisiae at a rate of 5% v / v and the activated seed culture of Lactobacillus plantarum at a rate of 4% v / v into the mixed induction solution, and culture aerobicly at 30℃ and 150r / min for 24h to obtain the mixed induction culture solution.

[0055] 5. Take the remaining 77.7g of mixed medicinal powder, add 622mL of distilled water, place it in an ultrasonic-fermentation coupled reactor, add the mixed inoculum induction culture medium, stir evenly, and set the ultrasonic parameters as follows: frequency 28kHz, power density 0.1W / mL, using intermittent ultrasonic mode (ultrasound for 5min, pause for 15min, repeat); fermentation conditions are: temperature 30℃, rotation speed 150r / min, aeration rate 1.0vvm (sterile air introduced), fermentation time 48h; after fermentation, the fermentation broth is obtained.

[0056] 6. Heat the fermentation broth to 80°C, maintain for 30 min, and then rapidly cool to room temperature; centrifuge at 8000 r / min for 15 min, collect the supernatant, and then filter the supernatant through a 0.45 μm microporous membrane to obtain a clear filtrate; place the clear filtrate in a rotary evaporator and concentrate it under reduced pressure at 50°C and -0.08 MPa to the same volume as in Example 1 to obtain a traditional Chinese medicine composition for treating allergic rhinitis.

[0057] Comparative Example 4: A method for preparing a traditional Chinese medicine composition for treating allergic rhinitis, differing from Example 1 in that it omits the induction and expansion culture step, and includes the following steps: 1. Weigh the raw medicinal materials according to the prescription: 10g of Schizonepeta tenuifolia, 10g of Saposhnikovia divaricata, 10g of Stellaria dichotoma, 10g of Prunus mume, 10g of Schisandra chinensis, 10g of Glycyrrhiza uralensis, 10g of Atractylodes macrocephala, 15g of Astragalus membranaceus, 10g of Punica granatum peel, 6g of Mentha haplocalyx, and 10g of Platycodon grandiflorus. Divide the raw medicinal materials into two groups based on their chemical composition: the volatile oil saponin group consists of Schizonepeta tenuifolia, Saposhnikovia divaricata, Mentha haplocalyx, Stellaria dichotoma, and Platycodon grandiflorus, with a total weight of 46g; the polysaccharide and organic acid group consists of Astragalus membranaceus, Atractylodes macrocephala, Glycyrrhiza uralensis, Prunus mume, Schisandra chinensis, and Punica granatum peel, with a total weight of 65g. Place the volatile oil saponin group in an ultrafine pulverizer, cool it with liquid nitrogen during the pulverization process, maintain the material temperature ≤0℃, and perform low-temperature ultrafine pulverization. Pass the powder through a 100-mesh sieve to obtain the volatile oil saponin powder, and seal it for later use. Place the polysaccharide and organic acid group in a room-temperature pulverizer, pulverize it, pass it through a 60-mesh sieve to obtain the polysaccharide and organic acid powder, and seal it for later use.

[0058] 2. Thaw the cryopreserved tubes of *Saccharomyces cerevisiae* rapidly in a 37°C water bath, inoculate them into YPD liquid medium, and culture them at 30°C and 150 r / min until the logarithmic growth phase to obtain the artificial expansion broth of *Saccharomyces cerevisiae*; thaw the cryopreserved tubes of *Lactobacillus plantarum* rapidly in a 37°C water bath, inoculate them into MRS liquid medium, and culture them in an anaerobic environment at 37°C until the logarithmic growth phase to obtain the artificial expansion broth of *Lactobacillus plantarum*.

[0059] 3. Take 46g of volatile oil saponin powder, add 368mL of distilled water, place it in an ultrasonic-fermentation coupled reactor, and add the artificial culture medium of Saccharomyces cerevisiae according to the same bacterial count as in Example 1. Stir well and set the ultrasonic parameters as follows: frequency 28kHz, power density 0.1W / mL, intermittent ultrasonic mode (ultrasound for 5min, pause for 15min, repeat); fermentation conditions are: temperature 30℃, rotation speed 150r / min, aeration rate 1.0vvm (sterile air introduced), and fermentation time 36h. After fermentation, aerobic fermentation broth is obtained.

[0060] 4. Take 65g of polysaccharide organic acid powder, add 520mL of distilled water, place it in an ultrasonic-fermentation coupled reactor, and purge the air in the reactor with high-purity N2 for 10min to create an anaerobic environment. Calculate the bacterial count according to the same method as in Example 1, add artificial culture medium of Lactobacillus plantarum, stir evenly, and set the ultrasonic parameters as follows: frequency 40kHz, power density 0.08W / mL, using intermittent ultrasonic mode (ultrasound for 5min, pause for 15min, repeating the cycle). The fermentation conditions are: temperature 37℃, continuous N2 purging to maintain the anaerobic environment, static fermentation for 56h, and after fermentation, obtain the anaerobic fermentation broth.

[0061] 5. Combine the aerobic fermentation broth and the anaerobic fermentation broth, stir evenly to obtain a combined fermentation broth; heat the combined fermentation broth to 80℃, maintain for 30 min, and rapidly cool to room temperature; centrifuge at 8000 r / min for 15 min, collect the supernatant, and filter the supernatant through a 0.45 μm microporous membrane to obtain a clear filtrate; place the clear filtrate in a rotary evaporator and concentrate under reduced pressure at 50℃ and -0.08 MPa to 25% of the combined fermentation broth volume to obtain a traditional Chinese medicine composition for treating allergic rhinitis.

[0062] Experimental Test Experiment 1: Effects of Traditional Chinese Medicine Combinations on the Proliferation and Enzyme Gene Expression of Saccharomyces cerevisiae and Lactobacillus plantarum To investigate the effects of traditional Chinese medicine compositions on the proliferation and enzyme expression of *Saccharomyces cerevisiae* and *Lactobacillus plantarum*, the following experiment was designed: The volatile oil saponin group induction solution and the polysaccharide organic acid group induction solution were prepared according to the method of Example 1; YPD liquid culture medium was prepared: containing 10 g / L yeast extract, 20 g / L peptone, and 20 g / L glucose; MRS liquid culture medium was prepared: containing 10 g / L peptone, 10 g / L beef extract, 5 g / L yeast extract, 20 g / L glucose, 5 g / L sodium acetate, 2 g / L diammonium hydrogen citrate, 1 mL / L Tween 80, 2 g / L K2HPO4, 0.58 g / L MgSO4·7H2O, and 0.25 g / L MnSO4·H2O, pH 6.5.

[0063] The Saccharomyces cerevisiae experiment was conducted in two groups: the control group used YPD liquid culture medium, and the traditional Chinese medicine induction group used volatile oil saponin induction solution. Each group had three replicates.

[0064] The *Lactobacillus plantarum* experiment was conducted in two groups: the control group used MRS liquid culture medium, and the traditional Chinese medicine induction group used polysaccharide-organic acid induction solution. Three replicates were prepared for each group.

[0065] Saccharomyces cerevisiae and Lactobacillus plantarum were activated and cultured to the logarithmic growth phase (OD) according to the method in Example 1. 600 =1.0), as the seed culture. *Saccharomyces cerevisiae* was inoculated at 5% v / v into YPD medium (control group) and volatile oil saponin induction solution (traditional Chinese medicine induction group), and cultured at 30℃ with shaking at 150 rpm. *Lactobacillus plantarum* was inoculated at 4% v / v into MRS medium (control group) and polysaccharide organic acid induction solution (traditional Chinese medicine induction group), and cultured anaerobically at 37℃. Samples were taken from each group at 0, 6, 12, 18, 24, and 30 h of culture, and the following indicators were measured: Total bacterial count determination: At each sampling time point, culture media from the control group and the traditional Chinese medicine induction group were collected, shaken thoroughly, and immediately sampled for testing. The culture media samples were thoroughly shaken and mixed, and 200 μL of each sample was placed in a flat-bottomed transparent microplate, with three replicates per sample. Uninoculated blank culture media were used as blank samples. Using a multi-functional microplate reader, the detection wavelength was set to 600 nm, and the absorbance values ​​of each well were measured at this wavelength. The data were recorded, and a bacterial growth curve was plotted. The experimental results are as follows: Figure 1 As shown in the figure; where figure a is the growth curve of Saccharomyces cerevisiae and figure b is the growth curve of Lactobacillus plantarum.

[0066] Key enzyme gene expression detection: 30-hour bacterial cells were collected, total RNA was extracted, reverse transcribed into cDNA, and detected by real-time quantitative PCR. Target genes detected in *Saccharomyces cerevisiae* included the hexokinase gene (…). HXK2 ), glyceraldehyde-3-phosphate dehydrogenase gene ( TDH3 ), enolase gene ( ENO2 ), with actin gene ( ACT1 (This is used as an internal reference.) Target genes detected in *Lactobacillus plantarum* include the β-glucosidase gene (...). bglA ), protease gene ( pepN ), α-amylase gene ( amyA ),by 16S rRNA Genes were used as internal controls. The relative fold increase of the target gene expression in the herbal induction group was calculated with the target gene expression level in the control group normalized to 1.0. The experimental results are shown in Tables 1 and 2. Table 1 shows the expression results of key enzyme genes in *Saccharomyces cerevisiae*; Table 2 shows the expression results of key enzyme genes in *Lactobacillus plantarum*.

[0067] Table 1. Results of key enzyme gene expression detection in Saccharomyces cerevisiae

[0068] Table 2 Results of expression detection of key enzyme genes in Lactobacillus plantarum

[0069] from Figure 1 As can be seen from the results, the volatile oil saponin group induction solution and the polysaccharide organic acid group induction solution prepared in this experiment can significantly promote the proliferation of Saccharomyces cerevisiae and Lactobacillus plantarum. This indicates that the traditional Chinese medicine components in this patented formula can serve as effective growth promoters for Saccharomyces cerevisiae and Lactobacillus plantarum. The active ingredients in the traditional Chinese medicine induction solution can effectively promote the rapid proliferation of the strains, providing a sufficient source of live bacteria for subsequent deep fermentation.

[0070] As shown in Tables 1 and 2, the volatile oil saponin group induction solution and the polysaccharide organic acid group induction solution prepared in this experiment can specifically induce the upregulation of the expression of key metabolic enzyme genes in Saccharomyces cerevisiae and Lactobacillus plantarum. The volatile oil saponin group induction solution can upregulate the expression of key enzyme genes in the glycolysis pathway of Saccharomyces cerevisiae. HXK2 , TDH3 and ENO2 Expression; the polysaccharide-organic acid group induction solution can upregulate the β-glucosidase gene of Lactobacillus plantarum ( bglA ), protease gene ( pepN ) and α-amylase gene ( amyA The expression of ).

[0071] HXK2 The gene-encoded hexokinase is the first key enzyme in the glycolysis pathway, responsible for catalyzing the phosphorylation of glucose to glucose-6-phosphate, and is a key regulatory node in glucose metabolism. TDH3 The gene-encoded glyceraldehyde-3-phosphate dehydrogenase is an important oxidoreductase in the glycolysis pathway; ENO2 Enolase, encoded by the gene, is one of the rate-limiting enzymes in the glycolysis pathway. The synergistic upregulation of the above three key enzyme genes indicates that the volatile oil saponin group induction solution prepared in this patent can effectively activate the glycolysis metabolic pathway of Saccharomyces cerevisiae and enhance the sugar metabolism capacity of Saccharomyces cerevisiae.

[0072] bglA The gene-encoded β-glucosidase is a key enzyme in Lactobacillus plantarum that hydrolyzes saponins and flavonoids in traditional Chinese medicine. Its high expression helps to convert glycosides in traditional Chinese medicine into more active aglycones, thereby improving the efficacy of traditional Chinese medicine. pepN Gene-encoded proteases can hydrolyze proteins into polypeptides and amino acids, which helps to break down large protein molecules in traditional Chinese medicine and improve the absorbability of fermentation products. amyA The gene-encoded α-amylase can hydrolyze starch and other polysaccharides, promoting the degradation and utilization of carbohydrate components in traditional Chinese medicine. The synergistic upregulation of the above three types of enzyme genes indicates that the polysaccharide-organic acid group induction solution prepared in this patent can effectively activate the carbohydrate metabolism and nitrogen metabolism pathways of Lactobacillus plantarum, and enhance the ability of Lactobacillus plantarum to degrade and transform components of traditional Chinese medicine.

[0073] Experiment 2: Behavioral Evaluation Male SD rats were used as the research subjects to investigate the effects of a traditional Chinese medicine composition on serum indicators in rats with allergic rhinitis. Six-week-old male rats weighing 200±20g were selected and housed in an environment with a temperature of 22±1℃, a relative humidity of 40±15℃, and a light exposure time of 12h. During the experiment, rats had free access to food and water and underwent acclimatization for one week before the experiment began.

[0074] Rats were randomly divided into 10 groups, with 6 rats in each group: blank control group, model group, positive drug group, Example 1 group, Example 2 group, Example 3 group, comparative example 1 group, comparative example 2 group, comparative example 3 group and comparative example 4 group. A rat model of allergic rhinitis was established by basal sensitization through intraperitoneal injection of ovalbumin (OVA) combined with aluminum hydroxide (Al(OH)3) and local nasal provocation.

[0075] Add 0.3 mg OVA and 30 mg Al(OH)3 to 1 mL of 0.9% sterile saline and mix thoroughly to obtain an OVA suspension. On days 1, 3, 5, 7, 9, 11, and 13 of the experiment, rats in each group except the blank control group were intraperitoneally injected with 1 mL of the above OVA suspension per rat, once every other day, for a total of 7 injections. Rats in the blank control group were intraperitoneally injected with an equal volume of sterile saline, with the same number of injections and time as the model group. On day 15, rats in each group except the blank control group were instilled bilaterally with 50 mg / mL OVA solution (prepared with sterile saline), 50 μL per nasal cavity, once daily for 7 consecutive days. Rats in the blank control group were instilled with an equal volume of sterile saline nasally, with the same number of instillations and time as the model group. Nasal symptoms of rats were observed within 30 minutes after the last nasal instillation challenge, and behavioral scores were calculated using the superposition quantification method.

[0076] The scoring criteria are as follows: No sneezing: 0 points; 1-3 sneezes: 1 point; 4-10 sneezes: 2 points; 11 or more sneezes: 3 points; No clear nasal discharge: 0 points; Clear nasal discharge flowing to the front of the nostrils: 1 point; Clear nasal discharge flowing beyond the front of the nostrils: 2 points; Nasal discharge running all over the face: 3 points; No nose scratching: 0 points; Lightly wiping the nose a few times: 1 point; Frequent nose scratching: 2 points; Constant scratching of the nose and rubbing it everywhere: 3 points; A total score of ≥5 points is considered a successful model.

[0077] The day after successful model establishment, drug administration began: rats in each treatment group were administered the drug once daily by gavage for 14 consecutive days, with a dosage of 1 mL / 100 g body weight. The dosage was calculated based on the amount of raw drug and the rat's body weight; for the example group and the comparative group, the dosage was 10 g / kg of raw drug. The positive control group was administered loratadine suspension at a dose of 0.9 mg / kg by gavage. The blank control group and the model group were administered an equal volume of distilled water by gavage. During the drug intervention period, the model group and each treatment group continued to maintain sensitization by bilateral nasal drops of 50 mg / mL OVA solution (50 μL per side, every other day), while the blank control group was administered an equal volume of physiological saline by nasal drops.

[0078] Within 30 minutes after the last administration, rats in each group were placed in a transparent observation box and observed for symptoms such as nose scratching, runny nose, and sneezing using a double-blind method for 30 minutes. Scoring was performed using the above scoring criteria, and data analysis was conducted.

[0079] The results are shown in Table 3: Table 3 Results of the behavioral rating experiment

[0080] As shown in Table 3, the total behavioral score of the control group rats was 0.33±0.52, with virtually no sneezing, runny nose, or nasal scratching, indicating that normal rats did not exhibit nasal allergy symptoms. The total behavioral score of the model group rats was 6.50±0.55, significantly higher than that of the control group, indicating that the allergic rhinitis rat model was successfully established through intraperitoneal injection of OVA combined with local nasal provocation. The total behavioral score of the positive control group was 2.83±0.41, significantly lower than that of the model group, indicating that loratadine has a good therapeutic effect on allergic rhinitis rats.

[0081] Compared with the model group, the symptoms in Examples 1-3 were significantly reduced, indicating that the herbal composition of the present invention has a significant effect on improving sneezing, runny nose, and nasal scratching symptoms in rats with allergic rhinitis. Furthermore, the total behavioral scores of the three example groups were lower than those of the positive control group, indicating that the herbal composition of the present invention is superior to the positive control drug loratadine in improving nasal symptoms in rats with allergic rhinitis. Loratadine mainly works by antagonizing histamine H1 receptors, primarily targeting immediate-phase allergic symptoms. In contrast, the herbal composition of the present invention improves allergic rhinitis symptoms from multiple aspects through its multi-target overall regulatory effects of invigorating qi and strengthening the exterior, dispelling wind and opening the orifices, and astringing the lungs.

[0082] Comparative Example 1, using the conventional decoction method, showed a total behavioral score only 33.4% lower than the model group (P<0.05), but its efficacy was significantly lower than Example 1 (P<0.01). This indicates that the lack of a microbial fermentation transformation step makes it difficult for the macromolecular active ingredients in the medicinal materials to be fully released and transformed, seriously affecting the full realization of the therapeutic effect. Comparative Example 2, without ultrasound-assisted fermentation, showed a total behavioral score 46.2% lower than the model group (P<0.01), and its efficacy was significantly lower than Example 1 (P<0.01). This indicates that ultrasound-assisted fermentation plays an irreplaceable role in promoting the exchange of substances between the microbial strain and the medicinal substrate and accelerating the biotransformation of active ingredients; the lack of ultrasound assistance leads to a decrease in fermentation efficiency. Comparative Example 3, using a mixed fermentation scheme, showed a 41.1% decrease in total behavioral scores compared to the model group (P<0.01), and significantly lower efficacy than Example 1 (P<0.01). This indicates that fermenting volatile oil-based and polysaccharide-based medicinal materials in the same system leads to oxidative loss of volatile oil components during prolonged aerobic fermentation. Furthermore, the interaction between aerobic and anaerobic bacteria in the same system hinders the full utilization of their respective metabolic activities. Comparative Example 4, lacking an induction expansion culture step, showed a 35.8% decrease in total behavioral scores compared to the model group (P<0.05), and significantly lower efficacy than Example 1 (P<0.01). This indicates that the absence of a herbal induction culture step resulted in the bacteria entering the fermentation system without prior induction, leading to a long growth adaptation period and low metabolic activity, ultimately affecting fermentation efficiency and efficacy. The behavioral scores of all comparative example groups were significantly higher than those of Example 1 (P<0.01), demonstrating the synergistic effect of the three key technologies combined, fully showcasing the superiority of the synergistic process of grouped fermentation, ultrasound assistance, and induction expansion culture proposed in this invention.

[0083] Experiment 3: Effects of Traditional Chinese Medicine Composition on Indicators in Rats with Allergic Rhinitis Twenty-four hours after the last administration in Experiment 2, rats in each group were anesthetized by intraperitoneal injection of 3% sodium pentobarbital (1 mL / kg). The abdominal cavity was opened, the abdominal aorta was exposed, and blood was collected by puncturing the abdominal aorta with a disposable blood collection needle. Whole blood was collected in vacuum blood collection tubes without anticoagulants. After the whole blood was allowed to stand at room temperature for 30 min, it was centrifuged at 3000 r / min for 15 min to separate the serum. The serum was aliquoted into 1.5 mL sterile EP tubes, 50 μL per tube, labeled, and frozen at -80℃ to obtain peripheral serum samples for ELISA detection.

[0084] After blood collection, the rats were euthanized by cutting off their cervical vertebrae and bleeding them out. The rats' heads were quickly cut open, and the nasal cavity was cut along the nasal septum. The nasal septum mucosa and bilateral turbinate mucosa were carefully dissected with sterile ophthalmic forceps, flash-frozen in liquid nitrogen, and stored at -80°C for Western blot analysis.

[0085] The levels of OVA-specific immunoglobulin E (OVA-sIgE), interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13) in the peripheral serum of rats in each group were detected by enzyme-linked immunosorbent assay (ELISA). The results are shown in Table 4. Table 4. Results of detection of relevant protein levels in rat peripheral serum (U / mL)

[0086] As shown in Table 4, the serum levels of OVA-sIgE, IL-4, IL-5, and IL-13 in the model group rats were significantly higher than those in the blank control group (P<0.01), indicating that OVA sensitization successfully induced Th2 immune shift in AR rats. The serum levels of OVA-sIgE, IL-4, IL-5, and IL-13 in groups 1-3 were significantly lower than those in the model group (P<0.01), and there were no significant differences among the three groups in Examples 1-3 (P>0.05). Furthermore, all of these indicators were lower than those in the positive control group (loratadine), indicating that the herbal composition of this invention has the potential to inhibit Th2 immune inflammation better than simple antihistamines.

[0087] Comparative Example 1, using the conventional water decoction method, showed the smallest decrease in OVA-sIgE, IL-4, IL-5, and IL-13 levels among all comparative examples, indicating that the lack of a microbial fermentation transformation step limited the therapeutic effect. Comparative Example 2, without ultrasound-assisted fermentation, exhibited the best serum OVA-sIgE, IL-4, IL-5, and IL-13 levels among all comparative examples, but these were still significantly higher than in Example 1 (P<0.01), indicating that the lack of ultrasound-assisted treatment failed to maximize the release of the medicinal properties of the patented traditional Chinese medicine formula. The efficacy was assessed. Comparative Example 3, which used a mixed fermentation method with two strains, showed higher levels of OVA-sIgE, IL-4, IL-5, and IL-13 than Comparative Example 2. This indicates that the mixed fermentation of volatile oils and polysaccharides in the medicinal materials led to mutual inhibition between the two strains, affecting the full utilization of their respective metabolic activities. Comparative Example 4, which used a non-induced expansion culture scheme, showed higher levels of OVA-sIgE, IL-4, IL-5, and IL-13 than Comparative Example 3. This suggests that the strains, without prior stimulation from the traditional Chinese medicine, directly entered the fermentation system, resulting in low metabolic activity.

[0088] The above results confirm the synergistic effect of the three key technologies of this invention: group fermentation, ultrasound assistance, and induced expansion. Group fermentation allows the volatile oil saponin group and the polysaccharide organic acid group to be transformed by specific strains under their respective optimal conditions. Ultrasound assistance promotes the exchange of substances between the bacteria and the medicinal substrate through cavitation and microfluidic effects, accelerating biotransformation. Induced expansion enhances the adaptability of the strains to traditional Chinese medicine. The three technologies work together to improve the therapeutic effect, fully demonstrating the superiority of the overall process scheme of this invention.

[0089] Western blot was used to detect the protein expression levels of key proteins in the TLR4 / NF-κB signaling pathway, including TLR4, NF-κB p65, phosphorylated NF-κB p65 (p-NF-κB p65), IκB-α, and phosphorylated IκB-α (p-IκB-α), in the nasal mucosa tissue of rats in each group. ImageJ image analysis software was used to analyze the grayscale values ​​of the exposed protein bands. β-actin was used as an internal reference protein, and the grayscale ratio of each target protein band to the corresponding β-actin band was calculated, which represents the relative expression level of the target protein. The detection results are shown in Table 5. Table 5. Results of detection of key protein content in rat nasal mucosa tissue

[0090] Table 5 shows that the TLR4 / β-actin ratio, p-NF-κB p65 / NF-κB p65 ratio, and p-IκB-α / IκB-α ratio were all low in the nasal mucosa tissue of the blank control group, indicating that the TLR4 / NF-κB signaling pathway was at a low activation level in the nasal mucosa tissue under normal conditions. In the model group, these three indicators were significantly higher than those in the blank control group (P<0.01), indicating that repeated OVA stimulation induced high expression of TLR4 and excessive phosphorylation of NF-κB p65 and IκB-α in the nasal mucosa tissue, abnormally activating the TLR4 / NF-κB signaling pathway and promoting the transcription and release of a large number of Th2 inflammatory factors. In the positive control group, these three indicators were significantly lower than those in the model group (P<0.01), indicating that loratadine, while antagonizing histamine H1 receptors, also has a certain inhibitory effect on the TLR4 / NF-κB signaling pathway. All three indicators of the Example 1 to 3 groups were significantly lower than those of the model group (P < 0.01), and there was no significant difference among the three groups (P > 0.05). Among them, the three indicators of Example 1 group showed the largest decrease.

[0091] Comparative Example 1, using the conventional water decoction method, showed the smallest decrease in the three indicators among all comparative examples, indicating that the lack of microbial fermentation transformation steps resulted in insufficient release of macromolecular active ingredients, making it difficult to effectively inhibit the abnormal activation of the TLR4 / NF-κB signaling pathway. Comparative Example 4, without induction expansion, showed higher levels of the three indicators than Comparative Example 3, indicating that the lack of induction by traditional Chinese medicine led to insufficient metabolic activity, affecting the inhibitory effect on the TLR4 / NF-κB pathway. Comparative Example 3, using mixed fermentation, showed higher levels of the three indicators than Comparative Example 2, indicating that the mixed fermentation of volatile oils and polysaccharides led to mutual restraint among the microorganisms and oxidative loss of volatile oil components, weakening the pharmacodynamic material basis for inhibiting the TLR4 / NF-κB pathway. Comparative Example 2, without ultrasound-assisted fermentation, showed the best performance in the three indicators among the comparative examples, but was still significantly higher than Example 1 (P<0.01), indicating that the lack of ultrasound assistance led to insufficient exchange of microbial and medicinal substances, resulting in insufficient content of active ingredients in the fermentation product.

[0092] The above results indicate that the herbal composition of the present invention can reduce the transcription and release of downstream Th2 inflammatory factors (IL-4, IL-5, IL-13) by downregulating TLR4 protein expression in nasal mucosa, inhibiting IκB-α phosphorylation degradation and NF-κB p65 nuclear translocation activation, thereby blocking the abnormal activation of the TLR4 / NF-κB signaling pathway and reducing the local inflammatory response of the nasal mucosa.

[0093] Experiment 4: Effects of Traditional Chinese Medicine Composition on Liver and Kidney Function Indicators in Rats with Allergic Rhinitis The peripheral serum samples of rats extracted in Experiment 3 were used to detect biochemical indicators. Biochemical reagent kits were used to detect biochemical indicators such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), and blood urea nitrogen (UREA) in rat serum.

[0094] The rats in the above experiment were dissected, and their livers and kidneys were removed. The surface of the organs was rinsed with pre-cooled physiological saline to remove residual blood, and the surface moisture was absorbed with filter paper. The wet weight (g) of the liver and kidneys was measured and the data were recorded.

[0095] The detection results of ALT and AST are as follows Figure 2 As shown in the figure, figure a represents the results of ALT, and figure b represents the results of AST; the detection results of CREA and UREA are as follows. Figure 3 As shown in the figure, figure a represents the results of CREA, and figure b represents the results of UREA; the results of liver and kidney wet weight detection are as follows. Figure 4 As shown, Figure a shows the results of liver weight, and Figure b shows the results of kidney weight.

[0096] from Figures 2-4As can be seen, the serum ALT, AST, CREA, and UREA levels, as well as the wet weight of the liver and kidneys in the blank control group rats, were all within the normal physiological range. There were no significant differences in the above indicators between the model group and the blank control group (P>0.05), indicating that the OVA sensitization and repeated nasal instillation process itself did not significantly affect the liver and kidney function of rats with allergic rhinitis. There were no significant differences in serum ALT, AST, CREA, and UREA levels, as well as the wet weight of the liver and kidneys in each treatment group compared to the blank control group (P>0.05), indicating that the herbal composition of this invention and each comparative example did not have significant adverse effects on the liver and kidney function of rats at the administered dosage. There were no statistically significant differences between each example group and the blank control group, model group, and positive control group (P>0.05), and there were also no significant differences among the three example groups (P>0.05), indicating that different ratios within the scope of protection of this invention have good safety.

[0097] The above results indicate that the herbal composition of the present invention, when administered continuously for 14 days at the prescribed dosage, did not cause functional damage or organic changes in the liver and kidneys of rats with allergic rhinitis, demonstrating good drug safety.

[0098] The specific embodiments of the present invention described above do not constitute a limitation on the scope of protection of the present invention. Any other corresponding changes and modifications made in accordance with the technical concept of the present invention should be included within the scope of protection of the claims of the present invention.

Claims

1. A traditional Chinese medicine composition for treating allergic rhinitis, characterized in that, It is made from the following raw medicinal materials by weight through two-way fermentation with microorganisms including ultrasound assistance: 8-12 parts of Schizonepeta tenuifolia, 8-12 parts of Saposhnikovia divaricata, 8-12 parts of Stellaria dichotoma, 8-12 parts of Prunus mume, 8-12 parts of Schisandra chinensis, 8-12 parts of Glycyrrhiza uralensis, 8-12 parts of Atractylodes macrocephala, 12-18 parts of Astragalus membranaceus, 8-12 parts of Punica granatum peel, 4-8 parts of Mentha haplocalyx and 8-12 parts of Platycodon grandiflorus.

2. A method for preparing a traditional Chinese medicine composition for treating allergic rhinitis as described in claim 1, characterized in that, Includes the following steps: S1. Weigh each raw medicinal material according to the weight parts, and divide each raw medicinal material into volatile oil saponin group and polysaccharide organic acid group. Perform low-temperature ultrafine pulverization on the volatile oil saponin group and sieve to obtain volatile oil saponin group powder; perform room temperature pulverization on the polysaccharide organic acid group and sieve to obtain polysaccharide organic acid group powder. S2. Take 20-40% of the mass of the volatile oil saponin group powder and the polysaccharide organic acid group powder respectively to prepare the volatile oil saponin group induction solution and the polysaccharide organic acid group induction solution; inoculate Saccharomyces cerevisiae into the volatile oil saponin group induction solution for aerobic expansion culture to obtain Saccharomyces cerevisiae induction expansion solution; inoculate Lactobacillus plantarum into the polysaccharide organic acid group induction solution for anaerobic expansion culture to obtain Lactobacillus plantarum induction expansion solution; S3. Take the remaining volatile oil saponin powder, add 6-10 times the mass of distilled water, add Saccharomyces cerevisiae induction culture medium, and carry out aerobic ultrasonic fermentation culture to obtain aerobic fermentation broth; take the remaining polysaccharide organic acid powder, add 6-10 times the mass of distilled water, add Lactobacillus plantarum induction culture medium, and carry out anaerobic ultrasonic fermentation culture to obtain anaerobic fermentation broth. S4. Combine the aerobic fermentation broth and the anaerobic fermentation broth to obtain a combined fermentation broth, which is then sterilized, inactivated, separated from solids, and concentrated to obtain a traditional Chinese medicine composition for treating allergic rhinitis.

3. The method for preparing the traditional Chinese medicine composition for treating allergic rhinitis according to claim 2, characterized in that, In step S1, the volatile oil saponin group is composed of Schizonepeta tenuifolia, Saposhnikovia divaricata, Mentha haplocalyx, Stellaria dichotoma and Platycodon grandiflorus; the polysaccharide organic acid group is composed of Astragalus membranaceus, Atractylodes macrocephala, Glycyrrhiza uralensis, Prunus mume, Schisandra chinensis and Punica granatum peel.

4. The method for preparing the traditional Chinese medicine composition for treating allergic rhinitis according to claim 2, characterized in that, In step S2, the preparation method of the volatile oil saponin group induction solution is as follows: Take 20-40% of the mass of the volatile oil saponin group powder, add 6-10 times the mass of the powder in distilled water, soak for 20-40 minutes, decoct for 15-20 minutes, filter, and obtain the first decoction; add 4-8 times the mass of the powder in distilled water to the residue, decoct for 10-15 minutes, filter, and obtain the second decoction; combine the two decoctions, concentrate under reduced pressure, add 1-3% w / v glucose, sterilize, and obtain the volatile oil saponin group induction solution; The preparation method of the polysaccharide-organic acid group induction solution is as follows: Take 20-40% of the mass of the polysaccharide-organic acid group powder, add 6-10 times the mass of the powder in distilled water, soak for 40-60 minutes, decoct for 25-35 minutes, filter, and obtain the first decoction; add 4-8 times the mass of the powder in distilled water to the residue, decoct for 15-25 minutes, filter, and obtain the second decoction; combine the two decoctions, concentrate under reduced pressure, add 1-3% w / v glucose, sterilize, and obtain the polysaccharide-organic acid group induction solution.

5. The method for preparing the traditional Chinese medicine composition for treating allergic rhinitis according to claim 2, characterized in that, In step S2, the conditions for aerobic expansion culture are: temperature 28~32℃, rotation speed 120~180r / min, and culture time 18~30h; the conditions for anaerobic expansion culture are: temperature 35~39℃, anaerobic environment, and static culture for 18~30h.

6. The method for preparing the traditional Chinese medicine composition for treating allergic rhinitis according to claim 2, characterized in that, In step S3, the conditions for aerobic ultrasonic fermentation culture are: ultrasonic frequency 28kHz, power density 0.04~0.15W / mL, intermittent ultrasonic mode, fermentation temperature 28~32℃, rotation speed 120~180r / min, and fermentation time 24~48h; the conditions for anaerobic ultrasonic fermentation culture are: ultrasonic frequency 40kHz, power density 0.05~0.12W / mL, intermittent ultrasonic mode, fermentation temperature 35~39℃, anaerobic environment, and static fermentation for 48~60h.

7. The method for preparing the traditional Chinese medicine composition for treating allergic rhinitis according to claim 2, characterized in that, In step S4, the sterilization and inactivation method is pasteurization; the solid-liquid separation method is centrifugation and membrane filtration; and the concentration is vacuum concentration to 20-30% of the combined fermentation broth volume.

Images